Immunic, Inc. (IMUX)
Health Care · Clinical-stage immunology and neurology therapeutics · Nasdaq
Immunic is a late-stage biotech developing oral small-molecule therapies for multiple sclerosis and gastrointestinal diseases with Phase 3 data expected in 2026.
What Immunic, Inc. does
Immunic, Inc. is a late-stage biotechnology company developing oral small-molecule therapies for neurologic and gastrointestinal diseases. The company's lead candidate, vidofludimus calcium (IMU-838), is in Phase 3 clinical development for relapsing multiple sclerosis, while IMU-856 targets intestinal barrier function restoration for conditions like celiac disease and inflammatory bowel disease, and IMU-381 represents next-generation molecules in preclinical testing on the Nurr1 platform.
Themes: ["multiple sclerosis / MS neuroinflammation","oral small-molecule therapeutics","inflammatory bowel disease / IBD","neuroprotection","intestinal barrier restoration","autoimmune diseases"]
Fundamentals
- Price$14.77 as of 2026-07-10 close
- Market cap$201M as of 2026-07-13
- 1-year return+76.3% as of 2026-07-10 close
- ROE-130.3% as of 2026-07-13
- Debt / equity0.00 as of 2026-07-13
- Beta1.39 as of 2026-07-13
Key risks (from latest filing)
["Phase 3 ENSURE trial results for vidofludimus calcium in relapsing multiple sclerosis expected by end of 2026; failure to meet efficacy endpoints or safety concerns could significantly impact clinical development and regulatory approval prospects","Company is pre-revenue and dependent on capital raising to fund ongoing clinical trials; cash runway and future financing needs pose liquidity risk","Competitive landscape includes established MS therapies and other novel approaches; differentiation based on mechanism of action and safety profile may not be sufficient to achieve market adoption"]
Competitors & peers
- Biogen (BIIB)
- Celgene / Bristol Myers Squibb (BMY)
- Novartis (NVS)
- Roche (RHHBY)
- Merck (MRK)
- AbbVie (ABBV)
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.